Argenx
ARGX
#572
Rank
S$48.10 B
Marketcap
$804.47
Share price
0.99%
Change (1 day)
22.92%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

Argenx (ARGX) - Cash on Hand

Cash on Hand as of June 2024 : S$4.17 Billion

According to Argenx 's latest financial reports the company has S$4.17 Billion in cash and cash equivalents.
A companyโ€™s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.

Argenx - Cash on Hand chart (from 2021 to 2020)

Cash on Hand by year

Year Cash on Hand Change
2022-12-31S$2.93 B-6.96%
2021-12-31S$3.15 B-2.76%
2020-12-31S$3.24 B43.34%
2019-12-31S$2.26 B124.55%
2018-12-31S$1.00 B45.71%
2017-12-31S$0.69 B347.27%
2016-12-31S$0.15 B116.38%
2015-12-31S$71.57 M-34.56%
2014-12-31S$0.10 B94.97%
2013-12-31S$56.1 M59.13%
2012-12-31S$35.25 M-31.3%
2011-12-31S$51.32 M185.24%
2010-12-31S$17.99 M